Product Name:
LATS2-CT
Product Number:
ab-nk092-2
Target Full Name: Large tumour suppressor 2 protein-serine kinase
Target Alias: FLJ13161; KPM; ENSG00000150457
Product Type Specific: LATS2 protein kinase pan-specific antibody
Antibody Code: NK092-2
Antibody Target Type: Pan-specific
Protein UniProt: Q9NRM7
Protein SigNET: LATS2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human LATS2 (KPM) sequence peptide Cat. No.: PE-01BDO95
Antibody Immunogen Sequence: SQAESSDLESSDLVDQTEGC
Antibody Immunogen Description: Corresponds to amino acid residues S1064 to C1083; C-terminus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 120-145 kDa.
Related Product 1: LATS2 (1064-1083) antibody blocking peptide (Cat. No.: PE-01BDO95)
Related Product 2: LATSSubtide kinase substrate peptide (Cat. No.: PE-01BHU90)
Related Product 3: LATS2-ANT pan-specific antibody (Cat. No.: AB-NK092-1)
Related Product 4: LATS1-CT pan-specific antibody (Cat. No.: AB-NK091-2)
Related Product 5: LATS1-pS464 phosphosite-specific antibody (Cat. No.: AB-PK677)
Related Product 6: LATS1-pS909 phosphosite-specific antibody (Cat. No.: AB-PK678)
Scientific Background: LATS2 is a protein-serine/threonine kinase of the AGC group and NDR family, and serves as the core kinase that, along with STK3/MST2 and STK4/MST1, phosphorylates and inactivates YAP1 and TAZ, preventing their translocation into the nucleus. It is involved in cell-cycle regulation and spindle formation. LATS2 is localized to centrosomes during interphase to late metaphase by Aurora-A kinase. This is essential for centrosome duplication, mitotic apparatus maintenance, and maintaining genomic stability. LATS2 recruits gamma-tubulin for spindle formation. LATS2 may inhibit cell growth during arrest at the G1/S or G2/M check points. It acts as a regulator of the G1/S transition by downregulating cyclin E/CDK2 kinase activity. LATS2 expression is widespread in human tissues, with higher levels in the heart, skeletal muscle, and testis. LATS2 appears to function primarily as a tumour suppressor protein through activating p53 by physically inhibiting MDM2. Cancer-related mutations in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. K697A and S872A mutations lead to loss of tumour suppressor activity. Through a positive feedback mechanism, p53 can positively regulate expression of LATS2. Abberant expression of LATS2 either through downregulation or hypermethylation has been observed in various cancers including, lung, breast, hepatocellular, leukaemias, testicular, astrocytomas, retinoblastoma and head and neck cancers. S83E and S83C mutations in LATS2 lead to failure to localize at the centromere during interphase. LATS2 deletion in mice is lethal at embryonic states, which indicates that it may have a critical role in maintainance of mitotic fidelity and genomic integrity. This description may include information annotated by UniProt and/or Google AI.